Eris Lifesciences Q3 Results
- BSE: 540596
- NSE: ERIS
- ISIN: INE406M01024
- Sector: Biotechnology & Drugs
BSE
1,427.40
14.45 (1.02%)
14.45 (1.02%)Volume1.21 K
Updated: Fri 6 Feb, 2026 | 15:25:49
NSE
1,430.7017.50 (1.24%)
17.50 (1.24%)Volume25.81 K
Updated: Fri 6 Feb, 2026 | 15:30:02
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q3 Results Highlights
Quarter ended Dec 24
Note: Comparison is on QoQ basis
Quarterly - Eris Lifesciences Q3 Results
*All figures in crores except per share values
| Fiscal Period | Dec 24 | Sep 24 | QoQ Comp | Dec 23 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 558.34 | 557.14 | 0.22% | 356.50 | 56.62% |
| Depreciation/ Amortization | 81.20 | 80.48 | 0.89% | 45.72 | 77.62% |
| Operating Income | 169.11 | 184.03 | -8.11% | 129.79 | 30.29% |
| Net Income | 83.63 | 91.59 | -8.69% | 102.74 | -18.60% |
| Other Operating Expenses Total | 174.87 | 164.76 | 6.14% | 123.24 | 41.89% |
| Net Income Before Taxes | 116.16 | 129.11 | -10.03% | 115.87 | 0.25% |
| Total Revenue | 727.45 | 741.17 | -1.85% | 486.30 | 49.59% |
| Selling/ General/ Admin Expenses Total | 125.39 | 125.63 | -0.19% | 98.68 | 27.07% |
| Diluted Normalized EPS | 6.14 | 6.72 | -8.63% | 7.54 | -18.57% |